WCLC 2025 - Posters & ePosters-P1.17.64 Acinar Cell Lung Carcinoma: A Unique Subtype of NSCLC Adenocarcinoma,Insights From the AACR Project Genie Database

P1.17.64 Acinar Cell Lung Carcinoma: A Unique Subtype of NSCLC Adenocarcinoma,Insights From the AACR Project Genie Database

Back to course

Pdf Summary

This retrospective cohort study investigates acinar cell lung carcinoma (ACLC), a rare subtype of non-small cell lung cancer (NSCLC) adenocarcinoma, utilizing data from the AACR Project GENIE and cBioPortal. Among 798 patients analyzed—109 with ACLC and 689 with adenocarcinoma not otherwise specified (NOS)—clinical characteristics, genetic mutation profiles, and overall survival (OS) in stage IV disease were compared.<br /><br />Key findings show ACLC patients are older (median age 69.2 vs. 65.4 years), predominantly female (79.1% vs. 57.4%), and present more often at early stages (Stage I: 50% vs. 13%) compared to adenocarcinoma NOS. Despite earlier-stage diagnosis, ACLC patients in stage IV had comparable median OS (23.1 months vs. 27.6 months; p=0.5).<br /><br />Molecular analyses revealed ACLC’s distinct genetic profile with significantly lower TP53 mutation rates (43.33% vs. 56.5%) and absence of ROS1 alterations, unlike adenocarcinoma NOS where ROS1 mutations were present in 5.51% of cases. KRAS mutations were relatively more common in ACLC, though not statistically significant. Other targeted mutations such as EGFR, ALK, RET, MET, NTRK1, and BRAF were rare or less frequent in ACLC.<br /><br />Organ metastasis patterns in stage IV were similar across groups. The study underscores ACLC as a clinically and molecularly unique NSCLC subtype marked by older age at diagnosis, female predominance, early-stage detection, and distinct genetic makeup. However, limitations include the rarity of ACLC and reliance on retrospective data, calling for larger, prospective studies.<br /><br />In conclusion, ACLC should be recognized as a distinct NSCLC subtype. While early-stage characteristics differ from adenocarcinoma NOS, survival outcomes at advanced stages are similar, emphasizing the need for further research and tailored therapeutic strategies to improve management of this rare lung cancer subtype.

Asset Subtitle

Anas Zayed

Meta Tag

Speaker Anas Zayed

Topic Global Health, Health Services, and Health Economics

Keywords

acinar cell lung carcinoma

ACLC

non-small cell lung cancer

NSCLC

adenocarcinoma

AACR Project GENIE

cBioPortal

TP53 mutation

ROS1 alterations

KRAS mutations